What does NEWPHARMA GROUP do?

NEWPHARMA GROUP is a holding company in Liège. Public Limited, started on 7 November 2017, 1 establishment.

What is the address of NEWPHARMA GROUP?

The registered office of NEWPHARMA GROUP is located at Rue du Charbonnage 9, 4020 Liège.

Is NEWPHARMA GROUP still active?

Yes. According to the CBE (29 October 2026) NEWPHARMA GROUP is active, legal situation “Normale toestand”, started on 7 November 2017.

Is NEWPHARMA GROUP registered on Peppol?

Yes, NEWPHARMA GROUP is registered on the Peppol network with ID 0208:0684465652.

What is the enterprise number of NEWPHARMA GROUP?

The enterprise number of NEWPHARMA GROUP is BE0684465652.

When was NEWPHARMA GROUP founded?

NEWPHARMA GROUP was founded on 7 November 2017.

Who are the directors of NEWPHARMA GROUP?

According to the 2026 annual accounts, the directors of NEWPHARMA GROUP are: MICHAEL HAMELRIJCK, STEFAN GOETHAERT, JEF COLRUYT, KRIS CASTELEIN, JO WILLEMYNS, STEFAAN VANDAMME, GJ Lifescience management SRL.

Is NEWPHARMA GROUP a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 November 2017; 5 annual accounts filed, latest fiscal year 2026; 7 directors known from the annual account.

How much profit did NEWPHARMA GROUP make in 2026?

NEWPHARMA GROUP posted a profit after taxes of € 123,707 in financial year 2026.

What is the revenue of NEWPHARMA GROUP?

In its most recent annual accounts (2026), NEWPHARMA GROUP reported revenue of € 60,938,545.

How much does an employee at NEWPHARMA GROUP earn?

The average wage cost per full-time employee at NEWPHARMA GROUP was € 107,000 in 2026: staff costs of € 10.8 million for 100.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does NEWPHARMA GROUP have?

According to the 2026 annual accounts, NEWPHARMA GROUP has 100.9 full-time equivalents (FTE).

NEWPHARMA GROUP (Public Limited) - Liège - BE0684465652

Dossier NEWPHARMA GROUP, printed on 29 October 2026 from databakkes.be/en/0684465652/newpharma-group. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 41 % of short-term debt in 2026; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2026.
Board fully replaced NBB

No director from three years ago is still active according to annual account 2026.

Financials

Financial year 2026

NEWPHARMA GROUP from Liège, company number BE0684465652, closed financial year 2026 with a result of € 123,707 after tax. For that financial year NEWPHARMA GROUP recorded revenue of € 60.9 million and equity of € 86.8 million. Compared with financial year 2025, the result moved from € -42,260 to € 123,707. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 21, 2026.

What it is worth Growing

€ 86.8 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 123,707

▲ still € 42,260 loss in 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 21,524

▲ € 20,310 vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2026. Retained profit grew to € 81,445.

People and assets in 2026

Full-time equivalents

100.9

▲ 61.7 vs 2025

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 47.9 million in 2026, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 10.8 million

▲ 239% vs 2025

€ 107,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,989

▲ 10% vs 2025

Book value of vehicles, furniture and equipment.

Debts at end 2026

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 12 million

▲ 8% vs 2025

€ 2.2 million is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 8.6 million

▲ € 6.5 million vs 2025

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 64 days on average.

Taxes and wages

€ 1.5 million

▲ 131% vs 2025

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2024	2025	2026	Change 2025 → 2026
Revenue	€ 3,903,656 Revenue 2022: € 3,903,656 First fiscal year in the series	€ 8,352,719 Revenue 2024: € 8,352,719 ▲ 114% vs 2022 (€ 3,903,656) Favourable step	€ 7,772,440 Revenue 2025: € 7,772,440 ▼ 7% vs 2024 (€ 8,352,719) Unfavourable step	€ 60,938,545 Revenue 2026: € 60,938,545 ▲ € 53.2 million vs 2025 (€ 7,772,440) Favourable step	▲ € 53.2 million
Profit after taxes	€ -2,385,796 Profit after taxes 2022: € -2,385,796 First fiscal year in the series	€ -1,236,951 Profit after taxes 2024: € -1,236,951 ▲ € 1.1 million vs 2022 (€ -2,385,796) Favourable step	€ -42,260 Profit after taxes 2025: € -42,260 ▲ € 1.2 million vs 2024 (€ -1,236,951) Favourable step	€ 123,707 Profit after taxes 2026: € 123,707 ▲ € 165,967 vs 2025 (€ -42,260) Favourable step	▲ € 165,967
Equity	€ 60,982,223 Equity 2022: € 60,982,223 First fiscal year in the series	€ 79,745,273 Equity 2024: € 79,745,273 ▲ 31% vs 2022 (€ 60,982,223) Favourable step	€ 86,703,012 Equity 2025: € 86,703,012 ▲ 9% vs 2024 (€ 79,745,273) Favourable step	€ 86,837,159 Equity 2026: € 86,837,159 Unchanged (€ 86,703,012) Favourable step
Total debts	€ 34,858,205 Total debts 2022: € 34,858,205 First fiscal year in the series	€ 19,233,852 Total debts 2024: € 19,233,852 ▼ 45% vs 2022 (€ 34,858,205) Favourable step	€ 14,237,884 Total debts 2025: € 14,237,884 ▼ 26% vs 2024 (€ 19,233,852) Favourable step	€ 22,243,267 Total debts 2026: € 22,243,267 ▲ 56% vs 2025 (€ 14,237,884) Unfavourable step	▲ 56%
Cash	€ 8,602 Cash 2022: € 8,602 First fiscal year in the series	€ 36,661 Cash 2024: € 36,661 ▲ € 28,058 vs 2022 (€ 8,602) Favourable step	€ 1,214 Cash 2025: € 1,214 ▼ 97% vs 2024 (€ 36,661) Unfavourable step	€ 21,524 Cash 2026: € 21,524 ▲ € 20,310 vs 2025 (€ 1,214) Favourable step	▲ € 20,310
Retained profit	€ -6,517,777 Retained profit 2022: € -6,517,777 First fiscal year in the series	€ -7,754,727 Retained profit 2024: € -7,754,727 ▼ € 1.2 million vs 2022 (€ -6,517,777) Unfavourable step	€ -42,262 Retained profit 2025: € -42,262 ▲ € 7.7 million vs 2024 (€ -7,754,727) Favourable step	€ 81,445 Retained profit 2026: € 81,445 ▲ € 123,707 vs 2025 (€ -42,262) Favourable step	▲ € 123,707
Bank debt	€ 30,596,188 Bank debt 2022: € 30,596,188 First fiscal year in the series	€ 11,332,039 Bank debt 2024: € 11,332,039 ▼ 63% vs 2022 (€ 30,596,188) Favourable step	€ 11,124,310 Bank debt 2025: € 11,124,310 ▼ 2% vs 2024 (€ 11,332,039) Favourable step	€ 11,987,976 Bank debt 2026: € 11,987,976 ▲ 8% vs 2025 (€ 11,124,310) Unfavourable step	▲ 8%
Balance sheet total	€ 95,959,491 Balance sheet total 2022: € 95,959,491 First fiscal year in the series	€ 99,227,746 Balance sheet total 2024: € 99,227,746 ▲ 3% vs 2022 (€ 95,959,491) Unchanged	€ 101,104,339 Balance sheet total 2025: € 101,104,339 ▲ 2% vs 2024 (€ 99,227,746) Unchanged	€ 109,174,301 Balance sheet total 2026: € 109,174,301 ▲ 8% vs 2025 (€ 101,104,339) Unchanged	▲ 8%
Employees (FTE)	39.6 Employees (FTE) 2022: 39.6 First fiscal year in the series	41.9 Employees (FTE) 2024: 41.9 ▲ 2.3 vs 2022 (39.6) Unchanged	39.2 Employees (FTE) 2025: 39.2 ▼ 2.7 vs 2024 (41.9) Unchanged	100.9 Employees (FTE) 2026: 100.9 ▲ 61.7 vs 2025 (39.2) Unchanged	▲ 61.7

Key figures of NEWPHARMA GROUP, fiscal years 2022 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.

What happened to NEWPHARMA GROUP?

What happened at NEWPHARMA GROUP in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 STEFAN GOETHAERT stepped down as director. NBB
2028 JEF COLRUYT stepped down as director. NBB
2028 KRIS CASTELEIN stepped down as director. NBB
2028 JO WILLEMYNS stepped down as director. NBB
2027 GJ Lifescience management SRL stepped down as director. NBB
Oct 21, 2026 Corrected annual accounts filed for financial year 2026. Source: NBB ↗
2026 MICHAEL HAMELRIJCK became a director. NBB
2026 STEFAAN VANDAMME stepped down as director. NBB

In short

From € 2.4 million loss in 2022 to € 123,707 profit in 2026.

Paid € 69,797 in corporate taxes since 2022.

Best year ever: 2026, with € 123,707 profit.

Pays suppliers within 64 days on average.

Original PDFs at the National Bank ↗

Management

Sukhino SA 100%

NEWPHARMA GROUP

APOTHEEK NOORDERLAAN 100%

NEWPHARMA 100%

MEGAPARA SAS 100%

Apotheek Beaujean Centrum 100%

Behind NEWPHARMA GROUP is MICHAEL HAMELRIJCK. The shares are held by Sukhino SA (100%). It owns 100% of APOTHEEK NOORDERLAAN, 100% of NEWPHARMA, 100% of MEGAPARA SAS, 100% of Apotheek Beaujean Centrum, 100% of SMARTVALUE DISTRIBUTION SRL and 100% of Z+ PHARMA itself.

Directors

According to the 2026 annual accounts

MICHAEL HAMELRIJCK

Director

Also active at: Smartvalue Distribution

since 2026

STEFAN GOETHAERT

Director

Also active at: Smartvalue Distribution

since 2023 · until 2028

JEF COLRUYT

Director

since 2023 · until 2028

KRIS CASTELEIN

Director

Also active at: Smartvalue Distribution

since 2023 · until 2028

JO WILLEMYNS

Director

Also active at: Smartvalue Distribution

since 2023 · until 2028

STEFAAN VANDAMME

Director

Also active at: Smartvalue Distribution

since 2023 · until 2026

GJ Lifescience management SRL

Managing director · represented by GILLES JOURQUIN

Also active at: APOTHEEK BEAUJEAN CENTRUM, Smartvalue, NEWPHARMA

since 2021 · until 2027

Shareholders

Sukhino SA

100%

Participations

APOTHEEK NOORDERLAAN

100%

NEWPHARMA

100%

MEGAPARA SAS

100%

Apotheek Beaujean Centrum

100%

SMARTVALUE DISTRIBUTION SRL

100%

Z+ PHARMA

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Charbonnage 9

4020 Liège

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Smartvalue Distribution same network

€ 8,039 gross margin · 2026

Pranelya

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0684.465.652

VAT number

BE 0684.465.652

Registered office

Rue du Charbonnage 9, 4020 Liège

Names & denominations

NEWPHARMA GROUP

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

7 November 2017

Peppol

Active · Active since 3 Sept 2025

Activities · NACE

Activiteiten van hoofdkantoren

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

NEWPHARMA GROUP

Warning lights

Financials

What happened to NEWPHARMA GROUP?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions